Based on successful preclinical studies, several clinical trials have demonstrated that the combination of PI3K/PARP inhibitors sensitizes BRCA wild-type TNBC, ovarian, and breast cancers to PARPi (170, 171). Here, PARP1 is linked to breast carcinoma.